- Joined Pharmetheus in 2021, actively working in client projects, with continuous improvements, and as Project Portfolio Team Leader managing a team of MIDD consultants.
- Expertise includes model-informed drug development, clinical pharmacology and regulatory advices in therapeutic areas such as oncology/immuno-oncology, immuno-inflammation, cardiology, and diabetes.
- Experience as Head of Global Pharmacometrics and Clinical Pharmacokinetics at Servier, France, where she led a team supporting the drug development portfolio from research to submission including lifecycle management. Previously, she served as Head and Deputy Head of Clinical Pharmacometrics and Clinical Pharmacokinetics, and as a Pharmacometrician at Servier, France, and as Postdoctoral Fellow at the University of Manchester, UK.
- PharmD (2000) and M.Sc. in Pharmacokinetics (2000) from the University of Paris V, France, and Ph.D in Pharmacokinetics – PKPD modeling from the University of Poitiers, France.
Pharmetheus affiliated publications
Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive childrenA platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology frameworkPhysiologically based pharmacokinetic (PBPK) modeling of the oral absorption of 5-flucytosine to support further development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitisMechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology frameworkVirtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trialsHow to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an ExampleModeling Restoration of Gefitinib Efficacy by Co-Administration of MET Inhibitors in an EGFR Inhibitor-Resistant NSCLC Xenograft Model: A Tumor-in-Host DEB-Based ApproachMechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia